Late-stage biotech company developing potentially curative gene therapies through leveraging its proprietary NAV technology (consists of novel AAV vectors) Generates significant revenue through … [Read more...] about Regenxbio (RGNX)-About
biotech
GTHX Commercial Update 12/16/21-Transcript
Operator 0:10 Ladies and gentlemen, thank you for standing by and welcome to the G1 commercial update. At this time all participants are in listen only mode. After the speaker's presentation … [Read more...] about GTHX Commercial Update 12/16/21-Transcript
Gritstone Bio Reports Promising Preclinical Data in NHPs; Efficacy Threshold Exceeded at Low Doses
On 11/11/21 one of our core positions Gritstone Bio (GRTS) reported highly anticipated data from its CORAL COVID-19 vaccine program in non-human primates (NHPs). After scrupulous review and comparison … [Read more...] about Gritstone Bio Reports Promising Preclinical Data in NHPs; Efficacy Threshold Exceeded at Low Doses
GNMK Coverage Update
GenMark Diagnostics (Nasdaq: GNMK) Coverage Update 2/7/21 Outlook: Bullish PT = $20 (0-24 weeks) About GNMKÂ A commercial-stage medical-diagnostic company marketing its proprietary eSensor … [Read more...] about GNMK Coverage Update
Daily Trade Insights
BLCM #VolatilityWatch
Bellicum Pharmaceuticals (NASDAQ: BLCM) has been in continuous long-term downtrend since IPO. Stock price has been showing signs of a bottom (starting Aug 2019 to current) and with very successful … [Read more...] about BLCM #VolatilityWatch
Incoming Data + Gartley
Friday, October 11, 2019 About: ADVERUM BIOTECHNOLOGIES INC (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, ADVM is set … [Read more...] about Incoming Data + Gartley
Foamix Pharmaceuticals: A dermatology play with more than 100% upside potential
Foamix Pharmaceuticals (NASDAQ: FOMX) shares have been on a free fall for the past six months, declining by more than 30 percent to $2.3. The clinical-stage company which develops and commercializes … [Read more...] about Foamix Pharmaceuticals: A dermatology play with more than 100% upside potential
Sangamo Therapeutics Inc.(Nasdaq: SGMO) – Doom Or Gloom Scenario
Recent data release may have changed SGMO's future outlook. Sangamo's long-term chart suggests a potential pullback to $4 is a possibility, but that was before a recent data release by the company … [Read more...] about Sangamo Therapeutics Inc.(Nasdaq: SGMO) – Doom Or Gloom Scenario
Krystal Biotech (NASDAQ: KRYS) is On Track to Bring the First “Off the Shelf” Gene Therapy to Market
While writing my weekly Biopharma Stock Watch article for our members, I stumbled across an exciting clinical-stage gene therapy company Krystal Biotech (Nasdaq: KRYS). Since we started following KRYS … [Read more...] about Krystal Biotech (NASDAQ: KRYS) is On Track to Bring the First “Off the Shelf” Gene Therapy to Market
You must be logged in to post a comment.